Limonin Inhibits IL-1β-Induced Inflammation and Catabolism in Chondrocytes and Ameliorates Osteoarthritis by Activating Nrf2

Osteoarthritis (OA), a degenerative disorder, is considered to be one of the most common forms of arthritis. Limonin (Lim) is extracted from lemons and other citrus fruits. Limonin has been reported to have anti-inflammatory effects, while inflammation is a major cause of OA; thus, we propose that limonin may have a therapeutic effect on OA. In this study, the therapeutic effect of limonin on OA was assessed in chondrocytes in vitro in IL-1 beta induced OA and in the destabilization of the medial meniscus (DMM) mice in vivo. The Nrf2/HO-1/NF-kappa B signaling pathway was evaluated to illustrate the working mechanism of limonin on OA in chondrocytes. In this study, it was found that limonin can reduce the level of IL-1 beta induced proinflammatory cytokines such as INOS, COX-2, PGE2, NO, TNF-alpha, and IL-6. Limonin can also diminish the biosynthesis of IL-1 beta-stimulated chondrogenic catabolic enzymes such as MMP13 and ADAMTS5 in chondrocytes. The research on the mechanism study demonstrated that limonin exerts its protective effect on OA through the Nrf2/HO-1/NF-kappa B signaling pathway. Taken together, the present study shows that limonin may activate the Nrf2/HO1/NF-kappa B pathway to alleviate OA, making it a candidate therapeutic agent for OA.

Automated summary

The study found that limonin can alleviate symptoms of arthritis by activating the Nrf2/HO1/NF-kappa B pathway.